Johnson & Johnson has agreed to acquire Shockwave Medical Inc. in an all-cash deal with an enterprise value of about $13 billion, in a move that will boost its share of the market for medical ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Johnson & Johnson is working on a bid for $10bn neuroscience drugmaker Intra-Cellular Therapies, in what would be the biggest ...

Johnson & Johnson is buying medical-devices maker Shockwave Medical for a total enterprise value of about $13.1 billion.

Johnson & Johnson (J&J) is in discussions to acquire Intra-Cellular Therapies in the biggest biotech transaction in more than a year.

Johnson & Johnson remains a Buy for its stability and consistent dividends, despite short-term price fluctuations and modest ...

Johnson & Johnson has struck a $14.6bn deal to buy neuroscience drugmaker Intra-Cellular Therapies, the US pharmaceutical company said, marking the biggest biotech buyout in more than a year.

The deal would help accelerate growth in J&J's drugs business after the company spun off its consumer health unit in 2023.

It has made several transactions in the past few years to boost its pharmaceuticals and medical devices units, including a $13.1 billion deal for Shockwave ... has offered to buy each share ...